UPDATE — Abeona Therapeutics(R) and Lurie Children’s Open First Center for ZEVASKYN(TM) Gene Therapy to Treat Wounds in Painful Skin Disorder
(NASDAQ:ABEO), – ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. – – Ann & Robert H. Lurie Children's Hospital of Chicago, a top-ranked hospital, is ready to evaluate patients for ZEVASKYN treatment – – Abeona Assist(TM) comprehensive patient services program in […]